Analyse the Effect of Semaglutide on Vascular Structure and Function in Patients With Early Type 2 Diabetes

NCT05303857 on ClinicalTrials.gov · last registry update 2025-06-11

Finished 15 December 2023, after enrolling 107 people. Primary outcome, as filed: Central (aortic) pulse pressure assessed by Sphygmocor XCEL. semaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P4
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: University of Erlangen-Nürnberg Medical School
Sponsor type: Other
Enrollment: 107
Started: 2022-03-03
Primary completion: 2023-12-15 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Central (aortic) pulse pressure assessed by Sphygmocor XCEL

Conditions studied

Diabetes Mellitus, Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.